Second-trimester multifetal pregnancy reduction facilitates prenatal diagnosis before the procedure

Citation
E. Geva et al., Second-trimester multifetal pregnancy reduction facilitates prenatal diagnosis before the procedure, FERT STERIL, 73(3), 2000, pp. 505-508
Citations number
19
Categorie Soggetti
Reproductive Medicine","da verificare
Journal title
FERTILITY AND STERILITY
ISSN journal
00150282 → ACNP
Volume
73
Issue
3
Year of publication
2000
Pages
505 - 508
Database
ISI
SICI code
0015-0282(200003)73:3<505:SMPRFP>2.0.ZU;2-G
Abstract
Objective: To evaluate the pregnancy outcome of selective second-trimester multifetal pregnancy reduction (MFPR) compared to first-trimester MFPR. Design: Cohort analysis. Setting: In Vitro Fertilization Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. Patient(s): The study groups comprised 38 and 70 patients who underwent sel ective second-trimester MFPR (group 1) and first-trimester MFPR (group 2) a . mean gestational ages of 19.7 +/- 3.3 weeks and 11.7 +/- 0.7 weeks, respe ctively. Intervention(s): Ultrasenographically guided intracardiac injection of pota ssium chloride (KCI) solution. Main Outcome Measure(s): Pregnancy outcome and obstetric complications. Result(s): No statistically significant difference was found between group 1 and group 2 regarding mean gestational age at delivery (35.4 +/- 3.4 week s and 35.9 +/- 3.1 weeks, respectively); mean birth weight (2,318.9 +/- 565 .7 g and 2,138.1 +/- 529.4 g); and the incidence of obstetric complications . These complications included pregnancy loss (5.2% and 15.7%), pregnancy-i nduced hypertension (0 and 10%), discordancy (12% and 18.4%), intrauterine growth restriction (0 and 40%), and gestational diabetes (0% and 6%). Howev er, the rate of all pregnancy complications was lower among second-trimeste r MFPR patients. Conclusion(s): Selective second-trimester MFPR is associated with favorable perinatal outcome and may facilitate detection of structural and chromosom al anomalies before the procedure and selective reduction of the affected f etus. (C) 2000 by American Society for Reproductive Medicine.